Dr Toh Han Chong

Dr Toh Han Chong

Dr Toh Han Chong is Deputy CEO (Strategic Partnerships), National Cancer Centre Singapore and tenured Professor at Duke NUS Medical School. Dr Toh obtained the International Baccalaureate diploma at the Lester B. Pearson College, Canada on a United World College Scholarship. He obtained his BSc (Intercalated) from the University of London in ‘Infection and Immunity’ and his medical degree from the University of Cambridge, UK. His oncology and research training were at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas, USA. Dr Toh is alumni of the Harvard Business School General Management Program. He is Principal Lead, Cellular Immunotherapy at the Singhealth Duke NUS Cell Therapy Centre. Dr Toh is a council member at the Singapore Ministry of Health Agency for Care Effectiveness (ACE) and member of the Ministry of Health Clinical Services Strategy Committee for Cell Therapy.

Dr Toh is recipient of National Senior Clinician Scientist Award in 2017 and National Medical Excellence Award (NMEA) in 2018 for his pioneering work in cell and immunotherapy for cancer. He leads the NMRC Large Collaborative Grant VICTORY (Virus-Induced Cancers Translational Oncology and immunologY) grant and is recipient of the NMRC STaR Award 2022 focusing on the translational understanding and therapeutic development for viral and non-viral hepatocellular carcinoma.

He was founding Chief Medical Officer for Tessa Therapeutics and founder of clinical stage biotech NeoTILa, which won 1st prize at the Cambridge University Wolfson Entrepreneurship Competition in the global health category (3rd overall) in March 2024.

Dr Toh is European Society for Medical Oncology (ESMO) faculty for Cancer Immunology and on the ESMO Scientific Committee 2024. He is co-founder of the Asia-Pacific Gastrointestinal Cancer Summit (APGCS). He has published over 150 peer review journal papers.